From Seekingalpha · SA Transcripts · · 30s
Roivant Sciences Shares Phase 3 Uveitis Drug Results
Roivant Sciences reveals Phase 3 results for brepocitinib in non-infectious uveitis.
In brief
Roivant Sciences reveals Phase 3 results for brepocitinib in non-infectious uveitis. Roivant Sciences announced Phase 3 results for brepocitinib treating non-infectious uveitis. Originally reported by Seekingalpha.
Roivant Sciences
Roivant Sciences Ltd. published a slide deck discussing Phase 3 results for brepocitinib in non-infectious uveitis.
Phase 3 Results
The company shared findings on brepocitinib's effectiveness for non-infectious uveitis treatment.
Event Details
The slide deck was published by Roivant Sciences in conjunction with this event on NASDAQ:ROIV.
The essence
Roivant Sciences announced Phase 3 results for brepocitinib treating non-infectious uveitis.
